Table 2.
Unadjusted, health service use, costs and mortality (advanced prostate cancer cohort and controls)
| Age 66 - 74 years | Age ≥ 75 years | |||||||
|---|---|---|---|---|---|---|---|---|
|
Prostate cancer
cohort |
Controls |
Prostate cancer
cohort |
Controls | |||||
| Substa nce use (n=105 0) n (%) (Group 4) |
No substan ce use (n=743 4) n (%) (Group 3) |
Substa nce use (n=842 ) n (%) (Group 2) |
No substa nce use (n=743 3) n (%) (Group 1) |
Substa nce use (n=429 ) n (%) (Group 4) |
No substa nce use (n= 5334) n (%) (Group 3) |
Substa nce use (n=421 ) n (%) (Group 2) |
No substa nce use (n=533 5) n (%) (Group 1) |
|
| Any health service use n (%) | ||||||||
| Inpatient hospitaliza tions |
908 (86.5) |
4674(6 2.9) |
470 (55.5) |
2018 (27.1) |
342 (79.7) |
2966 (55.6) |
164 (38.9) |
1331 (24.9) |
| Outpatient hospital visits | 693 (66.0) |
2974 (40.0) |
543 (64.4) |
3705 (49.8) |
320 (74.6) |
2649 (49.7) |
186 (44.7) |
1938 (36.3) |
| ER visits | 769 (73.2) |
4395 (59.1) |
383 (45.2) |
1990 (26.5) |
257 (59.9) |
2187 (41.0) |
145 (34.4) |
1215 (22.8) |
| Costs in $ | ||||||||
| Mean (std dev) Median |
77247 (43337 ) 111141 |
47852 (91710) 21946 |
57505 (81732 ) 33374 |
26439 (53561 ) 7093 |
60760 (97268 ) 28730 |
38845 (76750 ) 13953 |
60089 (75766 ) 35954 |
32579 (52280 ) 13788 |
| Mortality n (%) | ||||||||
| All-cause | 380 (36.2) |
1783 (23.9) |
177 (20.9) |
792 (10.5) |
284 (66.2) |
3537 (66.3) |
184 (43.7) |
1894 (35.5) |
| Prostate cancer specific | 230 (21.9) |
1221 (16.4) |
176 (41.0) |
2417 (45.3) |
||||